About | Free Trial

Last Update


This profile was last updated on . .

Is this you? Claim your profile.

Wrong Joel Jessee?

Mr. Joel Jessee A.

CSO and Chief Executive Officer


Direct Phone: (301) ***-****       

Email: j***@***.com


200 Perry Parkway, Suite 1

Gaithersburg, Maryland 20877

United States

Find other employees at this company (9)

Background Information

Employment History

Chief Executive Officer and Chief Scientific Officer

Molecular Transfer Inc

President and Chief Executive Officer

Molecular Transfer Inc

CSO and Chief Executive Officer

GlobalStem Inc

Director of Research and Development

Life Technologies Corporation

Vice President of Research and Development

Life Technologies Corporation

Vice President of Research and Development

Atto Bioscience , Inc.

Chief Executive Officer

Transformation Biosciences

Vice President Research and Development

Transformation Biosciences


Molecular Transfer Inc


Masters degree
Virginia Tech.

Web References (10 Total References)

Molecular Transfer // Gaithersburg, MD

www.moleculartransfer.com [cached]

Joel Jessee, Chief Executive Officer and Chief Scientific Officer Joel has been in product development for life science reagents for over thirty years. Prior to founding MTI, Joel was Vice President of R&D at Life Technologies/Invitrogen and at Atto Biosciences. He spent twenty years at LTI where he developed and introduced some of the most well recognized products for transformation, transfection and gene expression. He received a Masters degree in biology from Virginia Tech. Joel is an inventor or co-inventor on numerous patents.

Drug Discovery Japan

www.healthtech.com [cached]

Dr. Joel A. Jessee, Life Technologies, Inc

Dr. Joel A. Jessee, Director of R&D, Life Technologies, IncThe selective isolation and expression of genes and gene families is dependent on several novel technologies which have been integrated into a rapid gene discovery platform.The technologies integral to this platform are a rapid cDNA library construction and normalization procedure.These library construction procedures allow for the creation of normalized libraries that have =5 x 106 primary clones and an average insert size of =1.2 Kb.Selective enrichment of genes is accomplished using a magnetic bead technology that enriches genes from cDNA libraries such that after a single enrichment cycle, as many as 80 % of all clones enriched are a specific gene family or gene.The Improved Gene Trapper System requires no ETOH or phenol extraction and is compatible with a 96-well format for high-throughput applications.Depending on the specific gene, as many as 80 % of the clones obtained using these technologies can have the open reading frame of that gene.

Transformation Biosciences Leadership Team

www.transformationbio.com [cached]

Joel Jessee CEO

Former V.P. R&D, Life Technologies/Invitrogen

Molecular Transfer // Gaithersburg, MD

www.moleculartransfer.com [cached]

said Joel Jessee, CEO at MTI.

Genome Tri-Conference 2001 - GENE FUNCTIONAL ANALYSIS

www.genometriconference.com [cached]

Mr. Joel Jessee, Life Technologies, Inc.

Mr. Joel Jessee, Life Technologies, Inc.Full-length protein coding sequences are the starting point for functional analysis.We have developed full-length normalized cDNA libraries, highly enriched for novel and full-length ORFs.Clones from these libraries are enabled with the Gateway site-specific recombination system so that rapid subcloning into various functional analysis systems can be accomplished without using standard cloning techniques.
10:05 Creation of Genomewide Protein Expression Libraries Using Random Activation of Gene Expression

Similar Profiles

Other People with this Name

Other people with the name Jessee

Danny Jessee
Jackson Construction Inc

Charles Jessee
Integra LifeSciences Corporation

Daniel Jessee

Tiffany Jessee
Largo Medical Center Inc

Brett Jessee
Southern Wine & Spirits

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory